Acutely administered @entity32015 ( @entity14842 , ' @entity32015 ') has been proposed to have long-term positive effects on @entity1005 ( @entity1005 ) symptoms when combined with psychotherapy. No preclinical data support a mechanistic basis for these claims. Given the persistent nature of psychotherapeutic gains facilitated by @entity14842 , we hypothesized that @entity14842 improves fear extinction learning, a key process in exposure-based therapies for @entity1005 . In these experiments, @entity19 were first exposed to cued fear conditioning and treated with drug vehicle or @entity14842 before extinction training 2 days later. @entity14842 was administered systemically and also directly targeted to brain structures known to contribute to extinction. In addition to behavioral measures of extinction, changes in mRNA levels of @entity9140 ( @entity9140 ) and @entity9830 were measured after @entity14842 treatment and extinction. @entity14842 (7.8 mg kg(-1)) persistently and robustly enhanced long-term extinction when administered before extinction training. @entity14842 increased the expression of @entity9830 in the amygdala and medial prefrontal cortex (mPFC), whereas increases in @entity9140 expression were observed only in the amygdala after extinction training. Extinction enhancements were recapitulated when @entity14842 (1  g) was infused directly into the basolateral complex of the amygdala (BLA), and enhancement was abolished when @entity9140 signaling was inhibited before extinction. These findings suggest that @entity14842 enhances fear memory extinction through a @entity9140 -dependent mechanism, and that @entity14842 may be a useful adjunct to exposure-based therapies for @entity1005 and other @entity148 characterized by altered fear learning.

XXXX facilitates fear extinction learning.

@entity9140 :: ('12064(Tax:10090)', 'Gene') :: ['Bdnf', 'brain-derived neurotrophic factor', 'BDNF'] @entity19 :: ('10090', 'Species') :: ['mice'] @entity32015 :: ('D018817', 'Chemical') :: ['ecstasy', '3,4-methylenedioxymethamphetamine'] @entity1005 :: ('MESH:D013313', 'Disease') :: ['post-traumatic stress disorder', 'PTSD'] @entity9830 :: ('14281(Tax:10090)', 'Gene') :: ['Fos'] @entity148 :: ('MESH:D001008', 'Disease') :: ['anxiety disorders'] @entity14842 :: ('MESH:D018817', 'Chemical') :: ['MDMA']
@entity32015 :: (D018817,Chemical) :: ['3,4-Methylenedioxymethamphetamine']
